CAR-T Cells Successfully Target Solid Tumors for First Time
Engineered immune cells show 78% response rate against previously resistant pancreatic cancer.
1The Breakthrough
In what oncologists are calling a watershed moment, a Phase II clinical trial has demonstrated that next-generation CAR-T cells can effectively target solid tumors — a challenge that has eluded immunotherapy researchers for over a decade .
2Trial Design
The trial, conducted at Memorial Sloan Kettering Cancer Center, enrolled 45 patients with metastatic pancreatic ductal adenocarcinoma who had failed at least two prior lines of therapy . The engineered T cells, targeting a novel combination of mesothelin and claudin-18.2, achieved an objective response rate of 78%.
3Dual-Targeting Approach
The key innovation was a dual-targeting approach combined with an armored CAR construct that secretes IL-15 to sustain T cell persistence in the immunosuppressive tumor microenvironment . Previous CAR-T attempts against solid tumors failed primarily due to T cell exhaustion.
4Survival Outcomes
Complete responses were observed in 31% of patients, with median progression-free survival extending to 14.2 months — a dramatic improvement over the 3.7-month median for standard chemotherapy in this population .
- 78% objective response rate in metastatic pancreatic cancer
- 31% complete response rate
- 14.2-month median progression-free survival
- Dual-targeting mesothelin + claudin-18.2 approach
- Armored CAR construct with IL-15 prevents T cell exhaustion
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Pancreatic Cancer.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Oncology Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
5,623 consumers have expressed interest in this topic. Researchers studying Pancreatic Cancer can see anonymized demand signals.
CAR-T Cells Successfully Target Solid Tumors for First Time
Engineered immune cells show 78% response rate against previously resistant pancreatic cancer.
1The Breakthrough
In what oncologists are calling a watershed moment, a Phase II clinical trial has demonstrated that next-generation CAR-T cells can effectively target solid tumors — a challenge that has eluded immunotherapy researchers for over a decade .
2Trial Design
The trial, conducted at Memorial Sloan Kettering Cancer Center, enrolled 45 patients with metastatic pancreatic ductal adenocarcinoma who had failed at least two prior lines of therapy . The engineered T cells, targeting a novel combination of mesothelin and claudin-18.2, achieved an objective response rate of 78%.
3Dual-Targeting Approach
The key innovation was a dual-targeting approach combined with an armored CAR construct that secretes IL-15 to sustain T cell persistence in the immunosuppressive tumor microenvironment . Previous CAR-T attempts against solid tumors failed primarily due to T cell exhaustion.
4Survival Outcomes
Complete responses were observed in 31% of patients, with median progression-free survival extending to 14.2 months — a dramatic improvement over the 3.7-month median for standard chemotherapy in this population .
- 78% objective response rate in metastatic pancreatic cancer
- 31% complete response rate
- 14.2-month median progression-free survival
- Dual-targeting mesothelin + claudin-18.2 approach
- Armored CAR construct with IL-15 prevents T cell exhaustion
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Pancreatic Cancer.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Oncology Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
5,623 consumers have expressed interest in this topic. Researchers studying Pancreatic Cancer can see anonymized demand signals.